Loading
Pharmacology and Obesity Treatment · Journal article
Nutrients · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single-arm preclinical study in diet-induced obese mice examining Zanthoxylum bungeanum essential oil (ZBO) using multi-omics profiling. ZBO was associated with reductions in body weight gain, visceral adiposity, and hepatic steatosis, alongside alterations in gut microbiota composition and upregulation of lipid-oxidizing genes; however, the lack of a concurrent control group and reliance on surrogate molecular endpoints limit the strength of evidence.
Preclinical uncontrolled study in mice. HFD-induced obese (DIO) mice. Intervention: Zanthoxylum bungeanum essential oil (ZBO).
ZBO significantly mitigated HFD-induced body weight gain, visceral adiposity, hepatic steatosis, dyslipidemia, and glucose intolerance ZBO treatment was associated with upregulated mRNA expression of lipid-oxidizing genes (AMPK, PPAR-α, CPT1) and downregulated lipogenic genes (SREBP-1c, ACC, FAS, SCD1, LPL) ZBO was associated with increased gut microbial diversity, decreased Firmicutes/Bacteroidota ratio, and enrichment of beneficial taxa (Ligilactobacillus, Alistipes)
Findings are in mice and generalizability to humans is unknown; efficacy, safety, and dose in humans not evaluated
These findings are preclinical and do not yet support clinical use. Further controlled studies in animal models and subsequent human trials are necessary before any dietary or therapeutic recommendation can be made.
Single uncontrolled preclinical study in diet-induced obese mice using surrogate endpoints (body weight, lipid markers, gene expression) with no comparator group, providing early-phase evidence requiring confirmation in controlled trials and human studies.
As stated by the source record.
Quoted from the source exactly as published.
These findings are preclinical and do not yet support clinical use. Further controlled studies in animal models and subsequent human trials are necessary before any dietary or therapeutic recommendation can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Obesity is a metabolic disorder characterized by excessive lipid accumulation, disrupted fatty acid homeostasis, and gut microbiota dysbiosis. Zanthoxylum bungeanum essential oil (ZBO) is a natural plant volatile oil with diverse bioactivities, but its anti-obesity effects and potential associations remain unclear. Methods: HFD-induced obese (DIO) mice were evaluated to determine the effects of ZBO. Physiological parameters, glucose tolerance, and serum biochemical markers were assessed. Potential correlates were explored using a multi-omics approach, including integrated serum untargeted metabolomics, 16S rRNA gene sequencing, and RT-qPCR analysis of key genes involved in lipid metabolism in the liver and white adipose tissue. Results: ZBO significantly mitigated HFD-induced body weight gain, visceral adiposity, hepatic steatosis, dyslipidemia, and glucose intolerance. Metabolomics indicated that ZBO administration was associated with alterations in the serum metabolic landscape, particularly in pathways related to fatty acid metabolism and AMPK/PPAR-α signaling. Consistently, ZBO treatment was associated with upregulated mRNA expression of lipid-oxidizing genes (AMPK, PPAR-α, CPT1) and downregulated lipogenic genes (SREBP-1c, ACC, FAS, SCD1, LPL). 16S rRNA sequencing suggested that ZBO was associated with increased gut microbial diversity, decreased the Firmicutes/Bacteroidota ratio, and enriched beneficial taxa (e.g., Ligilactobacillus, Alistipes) while suppressing pro-inflammatory genera. Correlation analysis established robust associations between ZBO-modulated microbes and key fatty acid metabolites, particularly acylcarnitines and AMPK/PPAR-α-related intermediates. Conclusions: Collectively, these multi-omics data suggest that ZBO administration is associated with remodeling of the gut microbiota and correlated changes in fatty acid metabolic pathways. These findings provide preliminary preclinical evidence supporting further investigation of ZBO in the context of dietary strategies for alleviating HFD-induced obesity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.